RNA-DNA differences are rarer in proto-oncogenes than in tumor suppressor genes by Gao, Feng et al.
RNA-DNA differences are rarer in
proto-oncogenes than in tumor
suppressor genes
Feng Gao
1*, Yan Lin
1* & Randy Ren Zhang
2
1Department of Physics, Tianjin University, Tianjin 300072, China,
2Center for Molecular Medicine and Genetics, School of
Medicine, Wayne State University, Detroit 48201, USA.
It has long been assumed that DNA sequences and corresponding RNA transcripts are almost identical; a
recent discovery, however, revealed widespread RNA-DNA differences (RDDs), which represent a largely
unexplored aspect of human genome variation. It has been speculated that RDDs can affect disease
susceptibilityandmanifestations;however,almostnothingisknownabouthowRDDsarerelatedtodisease.
Here, we show that RDDs are rarer in proto-oncogenes than in tumor suppressor genes; the number of
RDDsincodingexons,butnotin39UTRand59UTR,issignificantlylowerintheformerthanthelatter,and
this trend is especially pronounced in non-synonymous RDDs, i.e., those cause amino acid changes. A
potential mechanism is that, unlike proto-oncogenes, the requirement of tumor suppressor genes to have
both alleles affected to cause tumor ‘buffers’ these genes to tolerate more RDDs.
P
roteins are translated from mRNAs, which are transcribed from genomic DNA. It has long been assumed
that DNA sequences and corresponding RNA transcripts are almost identical; a recent discovery, however,
revealedwidespreaddifferencesbetweenthem
1.CheungandcoworkerssequencedandcomparedDNAand
RNA sequences fromB cells of 27 human individuals, and found more than 10,000 sites that showed RNA-DNA
differences (RDD). Many of these RDDs were observed in other tissues, including primary skin cells and the
brain, from other unrelated individuals. Mass spectrometry showed that sequences of many proteins corre-
sponded to the RNA variants, rather than genomic DNA, indicating that the RNA forms were translated into
proteins
1.
This breakthrough represents a largely unexplored aspect of human genome variation. Traditionally, genetic
studieshavebeenfocusedonDNAsequencepolymorphisms,butbecauseofthepresenceofRDDs,futurestudies
willlikelyalsoneedtoincludeRNAvariants.IthasbeenspeculatedthatRDDscanaffectdiseasesusceptibilityand
manifestations
1; however, almost nothing is known about how RDDs are related to disease.
Here, we have examined whether RDD distributions differ between proto-oncogenes and tumor suppressor
genes. A proto-oncogene, which usually encodes proteins that regulate cell growth and differentiation, is a gene
that,duetomutations,canbecomeanoncogenetoinducetumors
2.Incontrast,atumorsuppressorgene,oranti-
oncogene, which usually encodes proteins that repress cell cycle or promote apoptosis, is a gene that protects
humans from tumor induction
3. Consequently, we found that proto-oncogenes have significantly rarer RDDs
than tumor suppressor genes, and this is especially pronounced for RDDs that lead to non-synonymous amino
acid changes.
Results
To examine if RDDs have different occurrence between tumor suppressor genes and proto-oncogenes, we
compared the RDD distributions between these 2 kinds of genes. Maizels and coworkers compiled a database
of tumor suppressor genes and proto-oncogenes by extensively searching the Online Mendelian Inheritance in
Man (OMIM) database as a primary source, followed by confirmation of gene classification based on published
literatures
4.
A gene can have RDDs in the 59 untranslated region (UTR), 39 UTR, and coding exons, and those in coding
exonscanbeeithersynonymousornon-synonymous.Thedatabasecontained55tumorsuppressorgenesand95
proto-oncogenes.WecalculatedthenumberofRDDspergeneforthe2classesofgenes.Tumorsuppressorgenes
andproto-oncogeneshad27and14RDDs,respectively,incodingexons.ThenumberofRDDpergene(0.491vs.
0.147) was more than 3 times higher in the former than the latter (Fig. 1). We performed the chi-square tests,
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0.01). Interestingly, the number of RDD at the 39 UTR and 59 UTR
showed no significant differences (Fig. 1). Because coding regions
usually have a more dominant role than 39UTR and 59 UTR, this
result seems to suggest that the RDD number difference in tumor
suppressor genes and proto-oncogenes is biologically meaningful.
If RDDs are indeed related to biological functions of the genes, we
would expect that the difference between the 2 kinds of genes to
become more pronounced in RDDs that lead to non-synonymous
amino acid changes, compared to synonymous RDDs. The numbers
of non-synonymous RDDs for tumor suppressor genes and proto-
oncogenes were 20 and 9, respectively (P , 0.01). The RDD number
per gene in tumor suppressor genes was about 4 times of that in
proto-oncogenes (0.364 vs. 0.095) (Fig. 2). Therefore, these data is
consistent with the notion that RDDs are related to gene functions.
EachgenecanhaveeitheroneormorethanoneRDDs.Inaddition
totheRDDnumberspergene,wethusalsocalculatedthe numberof
genes that contain RDDs, and consistent results were obtained. The
number of genes that contained RDD was 36 (65.45%) and 24
(25.26%) in tumor suppressor genes and proto-oncogenes, respect-
ively (p , 0.0001). The number of genes that contained non-syn-
onymous RDDs in tumor suppressor genes and proto-oncogenes
were 15 (27.27%) and 7 (7.37%) (P 5 0.0015), and those for syn-
onymous RDDs were 6 (10.91%) and 5 (5.26%), respectively (Fig. 3).
Therefore the number of genes that contained RDD was still about 4
times in tumor suppressor genes than in proto-oncogenes.
TofacilitatetheresearchonRDDs,wecreated adatabaseofRNA-
DNA differences (DRDD). The database contains detailed informa-
tion about RDDs, such as RDD location, involved base changes,
involved amino acid changes, if any, and sequences and names of
RDD-containing genes. The information is stored and operated by
anopen-sourcedatabasemanagementsystem,MySQL,whichallows
rapid data retrieval. Users can browse and search for RDD records,
andcanalsoBlastthequerygenesagainstthedatabase.Thedatabase
will be periodically updated to incorporate newly discovered RDDs,
e.g.,those in thereference
5.DRDDcan beaccessed fromthe website:
http://tubic.tju.edu.cn/drdd.
Discussion
Some mechanisms, such as transcriptional errors
6 and RNA edit-
ing
7,8, are known to explain the exceptions for the complete fidelity
from genomic DNA to mRNA. But transcription errors are very
uncommon because of proofreading and repair mechanism
9 and
RNA editing mainly only involves A to G transition
8. The RDDs
identified in
1 included a large number (in the order of thousands)
RDDeventsforallthepossible12categories,thatis,AtoC/G/T,Cto
A/G/T, G to A/C/T and T to A/C/G. Therefore, these RDDs suggest
unknown mechanisms that increase human genetic variation and
diversify the human proteome because many RNA variants are
translated into proteins that were identified by mass spectrometry
1.
Our results, for the first time, show that RDDs are much rarer in
proto-oncogenes than in tumor suppressor genes. The database was
compiled in the year 2006
4, and therefore, the result will still need to
be further validated by other studies, which hopefully include larger
and more updated datasets. Nevertheless, because the difference of
RDD numbers in tumor suppressor genes and proto-oncogenes is
relatively large (4 times of non-synonymous RDDs in the former vs.
the latter), the conclusion is not likely to change.
Our results indicate that proto-oncogenes are much intolerable to
RDDsthantumorsuppressorgenes.Onepossiblemechanismisthat,
unlike proto-oncogenes, tumor suppressor genes usually follow a
two-hit hypothesis
10, which suggests that both alleles that code for
Figure 1 | RNA-DNA differences (RDDs) are rarer in proto-oncogenes
than in tumor suppressor genes. The number of coding-region RDDs is
significantly lower in proto-oncogenes than in tumor suppressor genes,
while RDDs at 39 UTR and 59 UTR show no significant difference.
Figure 2 | Significantly lower number of non-synonymous RDDs in
proto-oncogenes than in tumor suppressor genes.
Figure 3 | Significantly lower percentage of RDD-containing genes in
proto-oncogenes than in tumor suppressor genes.
www.nature.com/scientificreports
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SCIENTIFIC REPORTS | 2 : 245 | DOI: 10.1038/srep00245 3aparticular gene mustbeaffected to causetumor. Ifonly oneallele is
affected, the other copy of the gene can still function to protect the
cell. In contrast, for oncogenes, mutations in one allele can lead to
tumor.Therefore, therequirement foraffectingbothallelesintumor
suppressor genes seems to have a ‘buffer’ effect for these genes to
tolerate more RDDs, compared to proto-oncogenes.
In summary, RDDs, a newly discovered phenomenon, represent a
largely unexplored area of human genome variation. Although it has
been speculated that RDDs are involved in disease susceptibility and
manifestations, no evidence is found to relate RDDs to disease. We
here show that RDDs are rarer in proto-oncogenes than in tumor
suppressor genes; the number of RDDs in coding exons, but not in
39UTRand59UTR,issignificantlylowerintheformerthanthelatter,
and this trend is especially pronounced in RDDs that cause non-
synonymous amino acid changes. This result suggests that proto-
oncogenes are more intolerable to RDDs than tumor suppressor
genes. A potential mechanism is that, unlike proto-oncogenes, the
requirementoftumorsuppressorgenestohavebothalleleaffectedto
cause tumor ‘buffers’ these genes to tolerate more RDDs.
During proofreading, we noticed a recent publication
11 which
suggested that rather than RNA editing events, these RDDs can be
the result of accurate transcription from paralogous genes, making
the issue of wide-spread human RDDs highly controversial. There-
fore,theprevalenceofhumanRDDsreportedinthereference
1needs
to be further confirmed by more studies in more tissues and with
more disease conditions. The observation made by Schrider et al.
11
appears to explain the majority of the RDDs observed in the ref-
erence
1. In that case, an alternative explanation for the RDD differ-
ence between proto-oncogenes and tumor suppressor genes
is that rather than RNA editing mechanisms, it may in fact reflect
the different distribution of paralogous genes between the 2 gene
classes. This possibility, however, needs to be addressed by future
studies.
Methods
The 10,210 RDDs, which reside in 4,741 known genes in the human genome, were
provided in reference
1. A database of tumor suppressor genes and proto-oncogenes
was used to compare RDD difference between the 2 classes of genes. The database,
which was based on extensively searching the Online Mendelian Inheritance in
Man (OMIM) database
4, contained 55 tumor suppressor genes and 95 proto-
oncogenes. HGNC symbols, which have been assigned by the HUGO Gene
NomenclatureCommittee(HGNC)asuniquegenesymbolsandnames, wereusedto
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